- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04827589
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Tirabrutinib in Subjects With Antihistamine-Resistant Chronic Spontaneous Urticaria
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Diagnosis of chronic spontaneous urticaria (CSU) (with or without urticarial dermatographism) for ≥ 6 months prior to screening
- Presence of itch and hives for ≥ 6 consecutive weeks prior to screening, refractory to nonsedating H1-antihistamines (according to local treatment guidelines) during that time
- Individuals must be maintained on approved H1-antihistamine doses as per the 2018 European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) guidelines (2018 EAACI/GA2LEN/EDF/WAO; ie, up to 4 times standard dosing) from 7 days prior to randomization.
- Individuals must have active disease defined as UAS7 ≥ 16 and HSS7 ≥ 8 during the 7 consecutive days (with no missing timepoints) prior to randomization (Day -7 to Day -1).
Key Exclusion Criteria:
Clearly defined underlying etiology for chronic urticaria other than CSU, including:
- Inducible urticaria as the only manifestation of disease (cold, heat, pressure, delayed pressure, aquagenic, contact, cholinergic, dermatographism)
- Known underlying genetic cause of urticaria or angioedema such as hereditary angioedema (C1-inhibitor deficiency)
- Urticarial dermatoses associated with a known diagnosis of an autoinflammatory syndrome or monoclonal gammopathy
- Diseases with possible urticarial manifestations such as urticarial vasculitis, erythema multiforme, or cutaneous mastocytosis
- Any other skin disease associated with chronic itching that could confound the study evaluation (eg, atopic dermatitis, psoriasis, bullous pemphigoid, and dermatitis herpetiformis)
- Previous treatment with omalizumab or any other monoclonal antibody used to treat CSU within 16 weeks prior to randomization
- Refractory to omalizumab or biosimilar
- Previous use of a Bruton's tyrosine kinase (BTK) inhibitor
- Any prior history of anaphylaxis
- Use of a nonbiologic investigational drug or participation in an investigational study involving biologic therapy within 90 days or 5 half-lives (whichever is greater) prior to randomization
- Intravenous immunoglobulin (IVIg) or plasmapheresis within 28 days prior to randomization
- Use of cyclosporine A, methotrexate, mycophenolate mofetil (or mycophenolic acid), or azathioprine within 28 days prior to randomization; or use of dupilumab within 16 weeks prior to randomization
- Routine (daily or every other day use for 5 or more consecutive days) of systemic corticosteroids within 28 days of randomization
- Use of intramuscular corticosteroids within 28 days of randomization
- Any clinically unstable disease states that would likely require rescue corticosteroids (eg, severe asthma) that may interfere with data interpretation
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tirabrutinib
Participant will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 8 weeks.
|
Tablets administered orally
Other Names:
|
Placebo Comparator: Placebo
Participants will receive placebo twice daily in addition to their standard-of-care therapy for up to 8 weeks.
|
Tablets administered orally
|
Experimental: Tirabrutinib, Open Label Extension
At Week 8, participants who have not discontinued the study drug will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 16 weeks.
|
Tablets administered orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 8.
Time Frame: Baseline; Week 8
|
The UAS7 is the sum of the Hives Severity Score Over 7 Days (HSS7) and Itch Severity Score Over 7 Days (ISS7). The possible range of the UAS7 is 0 to 42. A well-controlled urticaria response is defined as a UAS7 ≤ 6. Higher scores indicate high disease activity in hives and itch. Hives Severity Score (HSS) is defined as the number of hives recorded twice daily by the participant on a scale from 0 (none) to 3 (severe). HSS7 is derived by adding together the daily average scores over a consecutive 7-day period. The severity of itch will be recorded twice daily by the participant using a scale from 0 (none) to 3 (severe). ISS7 is derived by adding together the daily average scores over a consecutive 7-day period. |
Baseline; Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of Hives Severity Score Over 7 Days (HSS7) at Week 8
Time Frame: Baseline; Week 8
|
Hives Severity Score (HSS) is defined as the number of hives recorded twice daily by the participant on a scale from 0 (none) to 3 (severe).
HSS7 is derived by adding together the daily average scores over a consecutive 7-day period.
The range of weekly scores is 0 to 21.
Higher scores indicate increase severity in hives.
|
Baseline; Week 8
|
Change from baseline of Itch Severity Score Over 7 Days (ISS7) at Week 8
Time Frame: Baseline; Week 8
|
The severity of itch will be recorded twice daily by the participant using a scale from 0 (none) to 3 (severe).
ISS7 is derived by adding together the daily average scores over a consecutive 7-day period.
The range of weekly scores is 0 to 21.
Higher scores indicate increase severity in itch.
|
Baseline; Week 8
|
Proportion of Participants Achieving a Complete Response (UAS7 = 0) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Proportion of Participants Achieving Well-controlled Urticaria (UAS7 ≤ 6) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Change from Baseline in Angioedema Activity Score Over 7 Days (AAS7) at Week 8
Time Frame: Baseline; Week 8
|
The Angioedema Activity Score (AAS) assesses the occurrence of episodes of angioedema.
The AAS will be recorded by the participant once daily.
A weekly score (AAS7) is derived by adding together the daily scores over a consecutive 7-day period.
The range of weekly scores is 0 to 105, with a higher score corresponding to greater severity.
|
Baseline; Week 8
|
Proportion of Participants Achieving a Complete Angioedema Response (AAS7 = 0) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Measurement at Week 8
Time Frame: Baseline; Week 8
|
The CU-Q2oL is a 23-item questionnaire.
Domains in the questionnaire include urticaria- and angioedema-specific symptoms, discomfort, sleep, mood and activities of daily living.
Each response is scored from 1 (no symptoms) to 5 (severe symptoms).
Individual responses are summed to produce the overall CU-Q2oL score, which is then converted to a 0 to 100-point scale.
A higher score indicates greater impairment in quality of life.
|
Baseline; Week 8
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-556-5960
- 2020-005394-27 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Spontaneous Urticaria
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UriticariaKorea, Republic of, Japan
-
United BioPharmaCompleted
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
United BioPharmaNot yet recruiting
-
United BioPharmaRecruiting
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingChronic Spontaneous UrticariaChina
-
UBP Greater China (Shanghai) Co., LtdNot yet recruitingChronic Spontaneous Urticaria
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States